These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 25617930)

  • 21. Determining triglyceride reductions needed for clinical impact in severe hypertriglyceridemia.
    Christian JB; Arondekar B; Buysman EK; Jacobson TA; Snipes RG; Horwitz RI
    Am J Med; 2014 Jan; 127(1):36-44.e1. PubMed ID: 24384100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recommendations for severe hypertriglyceridemia treatment, are there new strategies?
    Filippatos TD; Elisaf MS
    Curr Vasc Pharmacol; 2014; 12(4):598-616. PubMed ID: 23627980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapy and clinical trials.
    Usman M; Peter R
    Curr Opin Lipidol; 2006 Oct; 17(5):612-4. PubMed ID: 16960511
    [No Abstract]   [Full Text] [Related]  

  • 24. Hypertriglyceridemia and Cardiovascular Outcomes.
    Malhotra G; Sethi A; Arora R
    Am J Ther; 2016; 23(3):e862-70. PubMed ID: 25415545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new pure ω-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial.
    Jacobson TA
    Expert Rev Cardiovasc Ther; 2012 Jun; 10(6):687-95. PubMed ID: 22894624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia.
    Patel AA; Budoff MJ
    Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):145-9. PubMed ID: 26825470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT.
    Singh N; Bhatt DL; Miller M; Steg PG; Brinton EA; Jacobson TA; Jiao L; Tardif JC; Mason RP; Ballantyne CM;
    J Am Coll Cardiol; 2022 Jan; 79(2):220-222. PubMed ID: 35027114
    [No Abstract]   [Full Text] [Related]  

  • 28. Isosapent ethyl (Vascepa) for severe hypertriglyceridemia.
    Med Lett Drugs Ther; 2013 Apr; 55(1415):33-4. PubMed ID: 23836343
    [No Abstract]   [Full Text] [Related]  

  • 29. Role of fibrates in the management of hypertriglyceridemia.
    Rader DJ; Haffner SM
    Am J Cardiol; 1999 May; 83(9B):30F-35F. PubMed ID: 10357573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Defining the Role of Icosapent Ethyl in Clinical Practice.
    Chatterjee S; Hajra A; Bandyopadhyay D; Ghosh RK; Deedwania PC
    Am J Cardiovasc Drugs; 2020 Dec; 20(6):517-524. PubMed ID: 32157567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Fibrates: their prescription must be restricted].
    Béliard-Lasserre S
    Rev Prat; 2015 Dec; 65(10):1243-4. PubMed ID: 26979011
    [No Abstract]   [Full Text] [Related]  

  • 32. The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial.
    Peters BS; Wierzbicki AS; Moyle G; Nair D; Brockmeyer N
    Clin Ther; 2012 Jan; 34(1):67-76. PubMed ID: 22212377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Ballantyne CM;
    N Engl J Med; 2019 Jan; 380(1):11-22. PubMed ID: 30415628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.
    Durrington PN; Bhatnagar D; Mackness MI; Morgan J; Julier K; Khan MA; France M
    Heart; 2001 May; 85(5):544-8. PubMed ID: 11303007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
    Nelson JR; True WS; Le V; Mason RP
    Postgrad Med; 2017 Nov; 129(8):822-827. PubMed ID: 28974128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia.
    Skulas-Ray AC; West SG; Davidson MH; Kris-Etherton PM
    Expert Opin Pharmacother; 2008 May; 9(7):1237-48. PubMed ID: 18422480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial.
    Arbel Y; Klempfner R; Erez A; Goldenberg I; Benzekry S; Shlomo N; Fisman EZ; Tenenbaum A;
    Cardiovasc Diabetol; 2016 Jan; 15():11. PubMed ID: 26794137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are postprandial triglyceride and insulin abnormalities neglected cardiovascular risk factors in type 2 diabetes?
    Golay A
    Eur J Clin Invest; 2000 Aug; 30 Suppl 2():12-8. PubMed ID: 10975049
    [No Abstract]   [Full Text] [Related]  

  • 39. Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia.
    Grundy SM
    Am J Cardiol; 1998 Feb; 81(4A):1B-6B. PubMed ID: 9526806
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of omega-3 fatty acids on cardiovascular risk factors in patients with type 2 diabetes mellitus and hypertriglyceridemia: an open study.
    De Luis DA; Conde R; Aller R; Izaola O; González Sagrado M; Perez Castrillón JL; Dueñas A; Romero E
    Eur Rev Med Pharmacol Sci; 2009; 13(1):51-5. PubMed ID: 19364085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.